Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 1.00 |
| ▸ | TNF | P01375 | 8/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362205 | 1.00 | RIPK1 (1.00) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL860317 | 1.00 | RIPK1 (1.00) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL859928 | 1.00 | RIPK1 (1.00) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL29638037 | 1.00 | RIPK1 (1.00) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL860017 | 0.90 | RIPK1 (0.82) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL860449 | 0.90 | RIPK1 (0.82) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL860613 | 0.90 | RIPK1 (0.82) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL837405 | 0.89 | RIPK1 (0.80) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL16121816 | 0.88 | RIPK1 (0.78) | RIPK1TNFTP53GLACYP3A4 | |
| SCHEMBL16121917 | 0.88 | RIPK1 (0.78) | RIPK1TNFTP53GLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | EVERGREEN BIOSCIENCES (US) | 2024-08-06 | — | — | US | claimed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| EP-3731841-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | Evergreen Biosciences (US) | 2020-11-04 | — | — | EP | claimed |
| CN-111655258-A | Compositions for cryopreservation and methods of use thereof | 常青树生物科学公司 | 2020-09-11 | — | — | CN | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | EVERGREEN BIOSCIENCES (US) | 2019-07-04 | — | — | US | claimed |
| WO-2019006384-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-20170226514-A1 | PREVENTION OF TUMOUR METASTASIS BY INHIBITION OF NECROPTOSIS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-08-10 | — | — | US | claimed |
| EP-3180014-A1 | PREVENTION OF TUMOUR METASTASIS BY INHIBITION OF NECROPTOSIS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-21 | — | — | EP | claimed |
| WO-2016023918-A1 | PREVENTION OF TUMOUR METASTASIS BY INHIBITION OF NECROPTOSIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-02-18 | — | — | WO | claimed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | EVERGREEN BIOSCIENCES (US) | 2024-08-06 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2007075772-A2 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | BAK1, BAX, BAD | RIPK1 12/4885TNF 92/4885TP53 390/4885 |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | BAX, BAK1, CASP3 | RIPK1 22/4885TNF 67/4885TP53 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.